12:00 AM
Jun 22, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Adcirca tadalafil: Phase III data

Data from the double-blind, international Phase III PHIRST-1 trial in 405 patients showed that once-daily 40 mg Adcirca tadalafil met the primary endpoint of a significant increase in 6MWD vs. placebo at week 16 (p<0.01). The incidence of clinical worsening was reduced 68% in patients receiving 40 mg tadalafil...

Read the full 221 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >